Chemical Attachment of 5-Nitrosalicylaldimine Motif to Silatrane Resulting in an Organic-Inorganic Structure with High Medicinal Significance.
1-(3-aminopropyl)silatrane
2-hydroxy-5-nitrobenzaldehyde
azomethine
cytotoxicity
protein binding
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
18 Dec 2022
18 Dec 2022
Historique:
received:
21
11
2022
revised:
14
12
2022
accepted:
15
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
Two chemical motifs of interest for medicinal chemistry, silatrane as 1-(3-aminopropyl) silatrane (SIL M), and nitro group attached in position 5 to salicylaldehyde, are coupled in a new structure, 1-(3-{[(2-hydroxy-5-nitrophenyl)methylidene]amino}propyl)silatrane (SIL-BS), through an azomethine moiety, also known as a versatile pharmacophore. The high purity isolated compound was structurally characterized by an elemental, spectral, and single crystal X-ray diffraction analysis. Given the structural premises for being a biologically active compound, different specific techniques and protocols have been used to evaluate their in vitro hydrolytic stability in simulated physiological conditions, the cytotoxicity on two cancer cell lines (HepG2 and MCF7), and protein binding ability-with a major role in drug ADME (Absorption, Distribution, Metabolism and Excretion), in parallel with those of the SIL M. While the latter had a good biocompatibility, the nitro-silatrane derivative, SIL-BS, exhibited a higher cytotoxic activity on HepG2 and MCF7 cell lines, performance assigned, among others, to the known capacity of the nitro group to promote a specific cytotoxicity by a "activation by reduction" mechanism. Both compounds exhibited increased bio- and muco-adhesiveness, which can favor an optimized therapeutic effect by increased drug permeation and residence time in tumor location. Additional benefits of these compounds have been demonstrated by their antimicrobial activity on several fungi and bacteria species. Molecular docking computations on Human Serum Albumin (HSA) and M
Identifiants
pubmed: 36559331
pii: pharmaceutics14122838
doi: 10.3390/pharmaceutics14122838
pmc: PMC9781643
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Unitatea Executiva Pentru Finantarea Invatamantului Superior a Cercetarii Dezvoltarii si Inovarii
ID : PN-III-P4-ID-PCCF-2016-0050, Contract 4/2018, 5DnanoP
Références
J Med Chem. 2019 Mar 28;62(6):2851-2893
pubmed: 30295477
Bioorg Chem. 2020 Dec;105:104450
pubmed: 33189994
Chem Biol Drug Des. 2015 Oct;86(4):905-10
pubmed: 25599975
Future Sci OA. 2015 Aug 01;1(1):FSO44
pubmed: 28031862
J Mol Struct. 2022 Feb 15;1250:131782
pubmed: 34697505
Dokl Biol Sci. 2011 Jul-Aug;439:264-6
pubmed: 21953239
Int J Mol Sci. 2021 Aug 05;22(16):
pubmed: 34445120
J Pharm Anal. 2016 Feb;6(1):56-63
pubmed: 29403963
Int J Biol Macromol. 2020 Jun 1;152:503-515
pubmed: 32112841
Biophys Chem. 2010 Apr;147(3):146-52
pubmed: 20171005
J Chem Phys. 2006 Mar 28;124(12):124518
pubmed: 16599708
Chem Sci. 2020 Nov 12;11(48):12888-12917
pubmed: 34123239
Int J Biol Macromol. 2021 Aug 31;185:604-619
pubmed: 34216662
Biochim Biophys Acta. 2014 Dec;1844(12):2331-7
pubmed: 25308773
Mol Pharm. 2021 May 3;18(5):1862-1894
pubmed: 33787270
Antimicrob Agents Chemother. 1972 Dec;2(6):492-8
pubmed: 4670442
Bioinformatics. 2014 Oct 15;30(20):2981-2
pubmed: 24996895
ACS Omega. 2021 Jan 12;6(3):2328-2339
pubmed: 33521471
Adv Sci (Weinh). 2022 Jan 05;9(8):2101935
pubmed: 35317221
Expert Opin Investig Drugs. 2004 Sep;13(9):1149-57
pubmed: 15330746
RSC Adv. 2022 Jan 28;12(6):3687-3695
pubmed: 35425367
Chem Phys Lett. 2021 Jan 16;763:138193
pubmed: 33223560
J Fluoresc. 2016 Jul;26(4):1415-9
pubmed: 27220624
New Microbes New Infect. 2019 Nov 30;34:100622
pubmed: 31956419
Molecules. 2020 Apr 20;25(8):
pubmed: 32326131
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Proteins. 2002 May 15;47(3):393-402
pubmed: 11948792
Molecules. 2022 May 31;27(11):
pubmed: 35684486
Clin Cancer Res. 2001 Nov;7(11):3314-24
pubmed: 11705842
Acta Crystallogr C Struct Chem. 2015 Jan;71(Pt 1):3-8
pubmed: 25567568
Eur J Med Chem. 2016 Jan 27;108:287-300
pubmed: 26695730
Bioorg Med Chem. 2019 Jan 1;27(1):188-195
pubmed: 30522900
Chemistry. 2009;15(5):1123-33
pubmed: 19072946
Biomedicines. 2021 May 17;9(5):
pubmed: 34067862
J Med Chem. 2013 Jan 24;56(2):388-405
pubmed: 23061607
Chem Soc Rev. 2011 Mar;40(3):1791-840
pubmed: 21170448
Bioorg Med Chem Lett. 2007 Jan 15;17(2):354-7
pubmed: 17095218
Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3914-9
pubmed: 16497833
Acta Crystallogr Sect E Struct Rep Online. 2011 Dec 1;67(Pt 12):o3255
pubmed: 22199764
Methods Mol Biol. 2015;1266:29-53
pubmed: 25560066
Mini Rev Med Chem. 2006 Oct;6(10):1169-77
pubmed: 17073717
Dalton Trans. 2015 Dec 21;44(47):20312-5
pubmed: 26506505